Literature DB >> 9377572

High levels of expression and nuclear localization of interleukin-1 beta converting enzyme (ICE) and CPP32 in favorable human neuroblastomas.

A Nakagawara1, Y Nakamura, H Ikeda, T Hiwasa, K Kuida, M S Su, H Zhao, A Cnaan, S Sakiyama.   

Abstract

Neuroblastomas frequently show spontaneous regression and differentiation, which may at least partly be regulated by signaling through nerve growth factor and its receptors, TRK-A and p75LNTR. We studied 52 neuroblastic tumors to test whether the cell death-related proteases, interleukin-1 beta converting enzyme (ICE), CPP32, and Ich-1, were involved in the regression of the tumors. High levels of expression of ICE and CPP32 were significantly correlated with a high level of TRK-A expression, single copy of N-myc, younger age, lower stages, and better prognosis. The immunohistochemical studies and Western analyses as well as the terminal dUTP-biotin nick end labeling (TUNEL) method revealed that both ICE and CPP32 were translocated from the cytoplasm into the nuclei in regressing, apoptotic tumor cells. Our results suggest that ICE and CPP32 cysteine proteases may play an important role in regulating the apoptotic process of the favorable neuroblastomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9377572

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Subcellular localization of CrmA: identification of a novel leucine-rich nuclear export signal conserved in anti-apoptotic serpins.

Authors:  Jose A Rodriguez; Simone W Span; Frank A E Kruyt; Giuseppe Giaccone
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

2.  Immunohistochemical analysis of pro- and active-caspase 3 in laryngeal squamous cell carcinoma.

Authors:  Andrej Cör; Joze Pizem; Nina Gale
Journal:  Virchows Arch       Date:  2004-03-25       Impact factor: 4.064

3.  Mechanisms of regression.

Authors:  Dirk M Elston
Journal:  Clin Med Res       Date:  2004-05

4.  Analysis of in vivo patterns of caspase 3 gene expression in primary hepatocellular carcinoma and its relationship to p21(WAF1) expression and hepatic apoptosis.

Authors:  Bao-Hua Sun; Jun Zhang; Bao-J Wang; Xi-Ping Zhao; You-Kun Wang; Zhi-Qun Yu; Dong-Liang Yang; Lian-Jie Hao
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

5.  Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells.

Authors:  Viralkumar Patel; Kumudha Balakrishnan; Michael J Keating; William G Wierda; Varsha Gandhi
Journal:  Blood       Date:  2014-12-23       Impact factor: 22.113

Review 6.  Alterations in the nucleocytoplasmic transport in apoptosis: Caspases lead the way.

Authors:  Gelina S Kopeina; Evgeniia A Prokhorova; Inna N Lavrik; Boris Zhivotovsky
Journal:  Cell Prolif       Date:  2018-06-26       Impact factor: 6.831

7.  Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer.

Authors:  Cheng-Lin Zhu; Qiang Huang
Journal:  Dig Dis Sci       Date:  2019-08-22       Impact factor: 3.199

8.  Expression of caspase-3 and c-myc in non-small cell lung cancer.

Authors:  Jin young Yoo; Chi Hong Kim; So Hyang Song; Byoung Yong Shim; Youn Ju Jeong; Meyung Im Ahn; Suji Kim; Deog Gon Cho; Min Seop Jo; Kyu Do Cho; Hong Joo Cho; Seok Jin Kang; Hoon Kyo Kim
Journal:  Cancer Res Treat       Date:  2004-10-31       Impact factor: 4.679

9.  Activation of inflammasomes requires intracellular redistribution of the apoptotic speck-like protein containing a caspase recruitment domain.

Authors:  Nicole B Bryan; Andrea Dorfleutner; Yon Rojanasakul; Christian Stehlik
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

10.  Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells.

Authors:  Michele Navarra; Marilena Celano; Jessica Maiuolo; Silvia Schenone; Maurizio Botta; Adriano Angelucci; Placido Bramanti; Diego Russo
Journal:  BMC Cancer       Date:  2010-11-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.